UA75322C2 - Use of mhc class ii ligands as adjuvant for vaccination and lag-3 for cancer immunotherapy - Google Patents

Use of mhc class ii ligands as adjuvant for vaccination and lag-3 for cancer immunotherapy Download PDF

Info

Publication number: UA75322C2
Authority: UA; Ukraine
Prior art keywords: cells; antigen; immune response; tumor; application according
Prior art date: 1997-07-25

Application number

UA2000020976A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Roussy Inst Gustave

Applied Research Systems

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-25

Filing date

1998-07-23

Publication date

2006-04-17

1998-07-23 Application filed by Roussy Inst Gustave, Applied Research Systems filed Critical Roussy Inst Gustave

2006-04-17 Publication of UA75322C2 publication Critical patent/UA75322C2/uk

Links

239000003446 ligand Substances 0.000 title claims abstract description 25
238000002619 cancer immunotherapy Methods 0.000 title abstract 2
238000002255 vaccination Methods 0.000 title description 4
239000002671 adjuvant Substances 0.000 title description 3
101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 title 1
239000000427 antigen Substances 0.000 claims abstract description 47
108091007433 antigens Proteins 0.000 claims abstract description 47
102000036639 antigens Human genes 0.000 claims abstract description 47
230000028993 immune response Effects 0.000 claims abstract description 37
102000043131 MHC class II family Human genes 0.000 claims abstract description 21
108091054438 MHC class II family Proteins 0.000 claims abstract description 21
230000001575 pathological effect Effects 0.000 claims abstract description 9
238000004519 manufacturing process Methods 0.000 claims abstract description 6
239000003814 drug Substances 0.000 claims abstract description 5
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
210000004027 cell Anatomy 0.000 claims description 98
206010028980 Neoplasm Diseases 0.000 claims description 71
210000001744 T-lymphocyte Anatomy 0.000 claims description 41
101710199257 Peripheral myelin protein 22 Proteins 0.000 claims description 28
102100035917 Peripheral myelin protein 22 Human genes 0.000 claims description 27
230000001404 mediated effect Effects 0.000 claims description 20
229960005486 vaccine Drugs 0.000 claims description 16
201000011510 cancer Diseases 0.000 claims description 11
239000012634 fragment Substances 0.000 claims description 11
229940126601 medicinal product Drugs 0.000 claims description 7
230000002265 prevention Effects 0.000 claims description 5
208000035473 Communicable disease Diseases 0.000 claims description 4
208000015181 infectious disease Diseases 0.000 claims description 4
239000013612 plasmid Substances 0.000 claims description 4
108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
230000001580 bacterial effect Effects 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 3
238000009169 immunotherapy Methods 0.000 claims description 3
230000003612 virological effect Effects 0.000 claims description 3
238000011398 antitumor immunotherapy Methods 0.000 claims description 2
230000003071 parasitic effect Effects 0.000 claims description 2
102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 2
108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 2
230000002708 enhancing effect Effects 0.000 claims 2
230000001939 inductive effect Effects 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 abstract description 3
230000000145 adjuvantlike effect Effects 0.000 abstract description 2
102000017578 LAG3 Human genes 0.000 abstract 2
101150030213 Lag3 gene Proteins 0.000 abstract 2
241000699670 Mus sp. Species 0.000 description 58
210000004881 tumor cell Anatomy 0.000 description 54
108090000623 proteins and genes Proteins 0.000 description 24
108700018351 Major Histocompatibility Complex Proteins 0.000 description 21
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 21
230000014509 gene expression Effects 0.000 description 17
238000004458 analytical method Methods 0.000 description 15
238000002474 experimental method Methods 0.000 description 15
235000018102 proteins Nutrition 0.000 description 14
102000004169 proteins and genes Human genes 0.000 description 14
210000004698 lymphocyte Anatomy 0.000 description 13
238000000034 method Methods 0.000 description 13
230000002163 immunogen Effects 0.000 description 11
230000004614 tumor growth Effects 0.000 description 10
230000000694 effects Effects 0.000 description 9
230000036039 immunity Effects 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
210000004988 splenocyte Anatomy 0.000 description 8
108020004414 DNA Proteins 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 7
150000001413 amino acids Chemical class 0.000 description 7
230000000259 anti-tumor effect Effects 0.000 description 7
239000004475 Arginine Substances 0.000 description 6
102000053602 DNA Human genes 0.000 description 6
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
101100298048 Mus musculus Pmp22 gene Proteins 0.000 description 6
208000006265 Renal cell carcinoma Diseases 0.000 description 6
235000004279 alanine Nutrition 0.000 description 6
210000000612 antigen-presenting cell Anatomy 0.000 description 6
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
239000012636 effector Substances 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
230000009885 systemic effect Effects 0.000 description 6
238000012360 testing method Methods 0.000 description 6
206010039491 Sarcoma Diseases 0.000 description 5
230000012010 growth Effects 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
238000001890 transfection Methods 0.000 description 5
102100034613 Annexin A2 Human genes 0.000 description 4
108090000668 Annexin A2 Proteins 0.000 description 4
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 4
108091054437 MHC class I family Proteins 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
230000006023 anti-tumor response Effects 0.000 description 4
230000009089 cytolysis Effects 0.000 description 4
210000004443 dendritic cell Anatomy 0.000 description 4
235000013922 glutamic acid Nutrition 0.000 description 4
239000004220 glutamic acid Substances 0.000 description 4
230000005847 immunogenicity Effects 0.000 description 4
230000006698 induction Effects 0.000 description 4
239000000203 mixture Substances 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 4
206010009944 Colon cancer Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
101001000631 Homo sapiens Peripheral myelin protein 22 Proteins 0.000 description 3
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
239000012678 infectious agent Substances 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000010254 subcutaneous injection Methods 0.000 description 3
241000283707 Capra Species 0.000 description 2
VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 2
102000016844 Immunoglobulin-like domains Human genes 0.000 description 2
108050006430 Immunoglobulin-like domains Proteins 0.000 description 2
102000013462 Interleukin-12 Human genes 0.000 description 2
108010065805 Interleukin-12 Proteins 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
230000003750 conditioning effect Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000005014 ectopic expression Effects 0.000 description 2
239000000945 filler Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229940117681 interleukin-12 Drugs 0.000 description 2
230000007774 longterm Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000013642 negative control Substances 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
231100000588 tumorigenic Toxicity 0.000 description 2
230000000381 tumorigenic effect Effects 0.000 description 2
239000012646 vaccine adjuvant Substances 0.000 description 2
229940124931 vaccine adjuvant Drugs 0.000 description 2
101150042008 ACO4 gene Proteins 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
206010002961 Aplasia Diseases 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
101100310927 Caenorhabditis elegans sra-4 gene Proteins 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241000689227 Cora <basidiomycete fungus> Species 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
101000651298 Homo sapiens TRAF-interacting protein with FHA domain-containing protein A Proteins 0.000 description 1
GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 1
102000043129 MHC class I family Human genes 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101001000630 Mus musculus Peripheral myelin protein 22 Proteins 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
102100027651 TRAF-interacting protein with FHA domain-containing protein A Human genes 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
230000005809 anti-tumor immunity Effects 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000005975 antitumor immune response Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
201000008274 breast adenocarcinoma Diseases 0.000 description 1
239000000872 buffer Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
229940030156 cell vaccine Drugs 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229960002743 glutamine Drugs 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
102000055277 human IL2 Human genes 0.000 description 1
GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
229940097277 hygromycin b Drugs 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
238000012151 immunohistochemical method Methods 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
210000001821 langerhans cell Anatomy 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
238000002803 maceration Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
235000019988 mead Nutrition 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
229940021993 prophylactic vaccine Drugs 0.000 description 1
238000012342 propidium iodide staining Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000009738 saturating Methods 0.000 description 1
210000005212 secondary lymphoid organ Anatomy 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
231100000617 superantigen Toxicity 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000002992 thymic effect Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
230000005851 tumor immunogenicity Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Zoology (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UA2000020976A 1997-07-25 1998-07-23 Use of mhc class ii ligands as adjuvant for vaccination and lag-3 for cancer immunotherapy UA75322C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP97401800A EP0893507A1 (fr)	1997-07-25	1997-07-25	Utilisation de ligands de MHC classe II (CD4 et LAG-3) comme adjuvants pour la vaccination de LAG-3 dans le traitement du cancer
PCT/EP1998/004621 WO1999004810A2 (fr)	1997-07-25	1998-07-23	Utilisation de ligands cmh de classe ii comme adjuvants pour la vaccination et utilisation de lag-3 dans le traitement du cancer

Publications (1)

Publication Number	Publication Date
UA75322C2 true UA75322C2 (en)	2006-04-17

Family

ID=8229825

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2000020976A UA75322C2 (en)	1997-07-25	1998-07-23	Use of mhc class ii ligands as adjuvant for vaccination and lag-3 for cancer immunotherapy

Country Status (19)

Country	Link
US (2)	US6410509B1 (fr)
EP (3)	EP0893507A1 (fr)
JP (1)	JP4723722B2 (fr)
KR (1)	KR100603075B1 (fr)
CN (1)	CN1184320C (fr)
AT (2)	ATE324455T1 (fr)
AU (1)	AU753738B2 (fr)
BR (1)	BR9811037A (fr)
CA (2)	CA2293805C (fr)
DE (2)	DE69841866D1 (fr)
DK (1)	DK1002108T3 (fr)
EA (3)	EA200300092A1 (fr)
EE (1)	EE200000039A (fr)
ES (1)	ES2262242T3 (fr)
IL (2)	IL134212A0 (fr)
NO (1)	NO20000378D0 (fr)
PT (1)	PT1002108E (fr)
UA (1)	UA75322C2 (fr)
WO (1)	WO1999004810A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE519779T1 (de) *	2001-09-19	2011-08-15	Roussy Inst Gustave	An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen
US20060240024A1 (en)	2003-02-28	2006-10-26	The Johns Hopkins University	T cell regulation
KR20050082389A (ko) *	2004-02-18	2005-08-23	메덱스젠 주식회사	직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
FR2868781B1 (fr) *	2004-04-13	2008-02-22	Immutep	Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
EP1777523A1 (fr) *	2005-10-19	2007-04-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthode pour pronostiquer la progression d'un cancer et les résultats du patient et les moyens pour performer la méthode
EP2044949A1 (fr) *	2007-10-05	2009-04-08	Immutep	Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes
WO2011031139A1 (fr)	2009-09-09	2011-03-17	Universiteit Utrecht Holding B.V.	Protéine ataq ou fragment de celle-ci pouvant être utilisé en tant que vaccin
SA110310855B1 (ar)	2009-11-13	2014-09-16	Laboratories Leti S L Unipersonal	استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
US9187751B2 (en)	2010-11-10	2015-11-17	Laboratorios Leti, S.L.	Adjuvant
GB201322626D0 (en)	2013-12-19	2014-02-05	Immutep S A	Combined preparations for the treatment of cancer
UA122479C2 (uk)	2014-01-24	2020-11-25	Дана-Фарбер Кенсер Інстітьют, Інк.	Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
CN103751778B (zh) *	2014-01-28	2016-09-28	复旦大学	3′-脱氧腺苷在制备广谱疫苗增效的免疫佐剂中的应用
EA201691765A1 (ru)	2014-03-14	2016-12-30	Новартис Аг	Молекулы антител против lag-3 и их применения
WO2016056596A1 (fr)	2014-10-07	2016-04-14	日本電気株式会社	Peptide dérivé de hsp70, et procédé de fabrication de composition pharmaceutique, inducteur d'immunité, et cellule présentatrice d'antigène permettant le traitement ou la prévention du cancer l'utilisant
WO2016094639A1 (fr) *	2014-12-10	2016-06-16	Wisconsin Alumni Research Foundation	Vaccins d'adn de plasmide mini-introniques en combinaison avec un blocage lag3
GB201500374D0 (en)	2015-01-09	2015-02-25	Immutep S A	Combined preparations for the treatment of cancer
US10526388B2 (en)	2015-03-09	2020-01-07	Cytlimic Inc.	Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells
AU2016244570B2 (en) *	2015-04-07	2020-08-27	Nec Corporation	Medicine
EP3294324A1 (fr)	2015-05-13	2018-03-21	Agenus Inc.	Vaccins pour le traitement et la prévention du cancer
MX2017016844A (es)	2015-07-16	2018-08-15	Biokine Therapeutics Ltd	Composiciones y procedimientos para tratar cancer.
US20180340025A1 (en)	2015-07-29	2018-11-29	Novartis Ag	Combination therapies comprising antibody molecules to lag-3
US10265379B2 (en)	2015-09-16	2019-04-23	Annabelle Rodriguez Oquendo	Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
WO2017046409A1 (fr)	2015-09-18	2017-03-23	Rijksuniversiteit Groningen	Inuline à longue chaîne pour stimuler une réponse immunitaire
CN108495651A (zh)	2015-12-17	2018-09-04	诺华股份有限公司	抗pd-1的抗体分子及其用途
US11291718B2 (en)	2016-10-11	2022-04-05	Cytlimic Inc.	Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
CN108204958A (zh) *	2016-12-19	2018-06-26	伊缪泰普有限公司	结合测定
EP3784688A2 (fr)	2018-04-26	2021-03-03	Agenus Inc.	Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
CN113271970A (zh) *	2018-09-27	2021-08-17	健诺西生物科学公司	治疗方法
JP2020138940A (ja)	2019-02-28	2020-09-03	テルモ株式会社	治療方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ226414A (en) *	1987-10-02	1992-07-28	Genentech Inc	Cd4 peptide adhesion variants and their preparation and use
WO1990001870A1 (fr) *	1988-08-22	1990-03-08	The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce	Vecteurs de retrovirus exprimant des cd4 solubles: therapie genique pour le sida
JPH02231083A (ja) *	1988-08-31	1990-09-13	Eisai Co Ltd	組換ナチュラルキラー細胞活性化因子
EP0385909B1 (fr) *	1989-03-03	1994-07-13	MicroGeneSys, Inc.	Kit ou composition pour la prévention ou le traitement des infections par HIV-1
EP0394827A1 (fr) *	1989-04-26	1990-10-31	F. Hoffmann-La Roche Ag	Polypeptides chimériques de CD4-immunoglobuline
FR2656800B1 (fr) *	1990-01-08	1992-05-15	Roussy Inst Gustave	Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5851828A (en) *	1991-03-07	1998-12-22	The General Hospital Corporation	Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
ES2249760T3 (es) *	1993-01-26	2006-04-01	The Trustees Of The University Of Pennsylvania (A Corporation Of Pennsylvania)	Composiciones y procedimientos de administracion de materias geneticas.
SE510135C2 (sv) *	1994-05-05	1999-04-19	Berol Nobel Ab	Vattenhaltig suspension av en cellulosaeter, sätt för dess framställning samt komposition
JP3700859B2 (ja) *	1994-05-06	2005-09-28	アンスティテュギュスタブルシ	Ｌａｇ−３タンパク質の可溶性ポリペプチドフラクション；製造方法、治療用製剤、抗イディオタイプ抗体
MX9700560A (es) *	1994-08-05	1997-05-31	Warner Lambert Co	Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales.
CZ172497A3 (en) *	1994-12-07	1997-10-15	Hoffmann La Roche	Fragments of monoclonal substance exhibiting immunosuppressor activity
CN1171117A (zh) *	1994-12-23	1998-01-21	实验室奥姆公司	Mhc－ⅱ结合和/或mhc－ⅱ模拟分子用于预防和/或治疗炎性疾病的用途
ES2191784T3 (es) *	1995-12-28	2003-09-16	Univ Johns Hopkins Med	Vacunas de tumores de citocinas paracrinas alogenicas.

1997
- 1997-07-25 EP EP97401800A patent/EP0893507A1/fr not_active Withdrawn
1998
- 1998-07-23 CA CA2293805A patent/CA2293805C/fr not_active Expired - Lifetime
- 1998-07-23 KR KR1020007000265A patent/KR100603075B1/ko not_active Expired - Fee Related
- 1998-07-23 EE EEP200000039A patent/EE200000039A/xx unknown
- 1998-07-23 EA EA200300092A patent/EA200300092A1/ru unknown
- 1998-07-23 ES ES98945090T patent/ES2262242T3/es not_active Expired - Lifetime
- 1998-07-23 CN CNB988075474A patent/CN1184320C/zh not_active Expired - Lifetime
- 1998-07-23 BR BR9811037-3A patent/BR9811037A/pt not_active IP Right Cessation
- 1998-07-23 DE DE69841866T patent/DE69841866D1/de not_active Expired - Lifetime
- 1998-07-23 JP JP2000503862A patent/JP4723722B2/ja not_active Expired - Lifetime
- 1998-07-23 PT PT98945090T patent/PT1002108E/pt unknown
- 1998-07-23 WO PCT/EP1998/004621 patent/WO1999004810A2/fr not_active Ceased
- 1998-07-23 EA EA200000161A patent/EA003740B1/ru not_active IP Right Cessation
- 1998-07-23 AT AT98945090T patent/ATE324455T1/de active
- 1998-07-23 CA CA2732570A patent/CA2732570C/fr not_active Expired - Lifetime
- 1998-07-23 EP EP98945090A patent/EP1002108B1/fr not_active Expired - Lifetime
- 1998-07-23 IL IL13421298A patent/IL134212A0/xx unknown
- 1998-07-23 AU AU92547/98A patent/AU753738B2/en not_active Expired
- 1998-07-23 UA UA2000020976A patent/UA75322C2/uk unknown
- 1998-07-23 EP EP06008545A patent/EP1698701B1/fr not_active Expired - Lifetime
- 1998-07-23 DE DE69834330T patent/DE69834330T2/de not_active Expired - Lifetime
- 1998-07-23 EA EA200200565A patent/EA005405B1/ru not_active IP Right Cessation
- 1998-07-23 AT AT06008545T patent/ATE478956T1/de not_active IP Right Cessation
- 1998-07-23 DK DK98945090T patent/DK1002108T3/da active
2000
- 2000-01-24 IL IL134212A patent/IL134212A/en not_active IP Right Cessation
- 2000-01-25 NO NO20000378A patent/NO20000378D0/no not_active Application Discontinuation
- 2000-01-27 US US09/492,113 patent/US6410509B1/en not_active Expired - Lifetime
2002
- 2002-01-10 US US10/041,600 patent/US7109026B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EA005405B1 (ru)	2005-02-24
ATE324455T1 (de)	2006-05-15
CA2293805C (fr)	2011-05-03
CN1265149A (zh)	2000-08-30
EE200000039A (et)	2000-10-16
AU753738B2 (en)	2002-10-24
DE69841866D1 (de)	2010-10-07
EP1002108B1 (fr)	2006-04-26
NO20000378L (no)	2000-01-25
US7109026B2 (en)	2006-09-19
IL134212A (en)	2012-03-29
JP2001510806A (ja)	2001-08-07
CA2732570A1 (fr)	1999-02-04
KR100603075B1 (ko)	2006-07-20
EA003740B1 (ru)	2003-08-28
US6410509B1 (en)	2002-06-25
ATE478956T1 (de)	2010-09-15
BR9811037A (pt)	2000-08-01
HK1030014A1 (en)	2001-04-20
CN1184320C (zh)	2005-01-12
CA2293805A1 (fr)	1999-02-04
KR20010021706A (ko)	2001-03-15
US20020192195A1 (en)	2002-12-19
NO20000378D0 (no)	2000-01-25
EP1002108A2 (fr)	2000-05-24
DE69834330D1 (de)	2006-06-01
DE69834330T2 (de)	2007-03-29
EP1698701A1 (fr)	2006-09-06
WO1999004810A2 (fr)	1999-02-04
CA2732570C (fr)	2014-11-18
WO1999004810A3 (fr)	1999-07-08
JP4723722B2 (ja)	2011-07-13
EP1698701B1 (fr)	2010-08-25
PT1002108E (pt)	2006-09-29
AU9254798A (en)	1999-02-16
EA200000161A1 (ru)	2000-10-30
EP0893507A1 (fr)	1999-01-27
IL134212A0 (en)	2001-04-30
EA200200565A1 (ru)	2002-10-31
EA200300092A1 (ru)	2003-06-26
ES2262242T3 (es)	2006-11-16
DK1002108T3 (da)	2006-08-21

Publication	Publication Date	Title
EA005405B1 (ru)	2005-02-24	Применение опухолевых клеток, трансфицированных днк, кодирующей lag-3 или cd4, для производства лекарственного препарата для профилактики или лечения злокачественных опухолей
AP1261A (en)	2004-03-19	Composition containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response.
CA2169635C (fr)	2002-11-12	Methode, compositions et dispositifs pour administrer des polynucleotides nus codant des peptides biologiquement actifs
JP4059920B2 (ja)	2008-03-12	癌自己関連抗原特異的ヒト細胞障害性ｔ細胞の産生とその使用
JP4900884B2 (ja)	2012-03-21	腫瘍抗原
JP2002515734A (ja)	2002-05-28	遺伝子改変された樹状細胞により媒介される免疫刺激
AU2006277295B2 (en)	2011-08-11	Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same
JP2022553192A (ja)	2022-12-22	癌ワクチン
WO1999061068A9 (fr)	2000-09-08	Vaccins contre le cancer de la prostate, et leurs methodes de fabrication, d'utilisation, et d'evaluation
KR20020001865A (ko)	2002-01-09	면역반응을 증강시키기 위한 가용성 공동자극 분자의 용도
Bronte et al.	2003	Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase
US20040191761A1 (en)	2004-09-30	Modified adenoviral E1A constructs and methods of use thereof
CA2321974A1 (fr)	1999-09-02	Antigene 791gp72 associe a une tumeur
JP4223813B2 (ja)	2009-02-12	免疫増強特性を有するムチンペプチド
Ludvíková et al.	2005	Use of polyclonal rabbit antibodies for detection of the bcr-abl fusion zone in cells transfected with experimental bcr-abl DNA vaccines
KR20260071971A (ko)	2026-05-20	Il-7 단백질 및 cd80 단백질을 포함하는 막단백질형태의 융합펩타이드 및 이의 항종양 용도
WO2024052542A2 (fr)	2024-03-14	Cocktail de peptides
WO1995012681A1 (fr)	1995-05-11	Procede relatif a l'ir-95
HK40088792A (en)	2023-10-06	Recombinant poxviruses for cancer immunotherapy
WO2001032843A9 (fr)	2002-08-15	Reconnaissance immunitaire renforcee de cellules pathogenes par l'expression de proteine de liaison de sequence consensus d'interferon (icsbp)
MXPA99012024A (en)	2000-08-01	Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment
Sukumar	2008	Mechanisms of Rejection of High Grade B Cell Lymphoma in Mice